Amendment: SEC Form SC 13G/A filed by QuidelOrtho Corporation
$QDEL
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/7/2025 | $33.00 | Buy → Neutral | Citigroup |
| 5/8/2025 | $44.00 | Hold → Buy | Jefferies |
| 12/11/2024 | $44.00 → $50.00 | Neutral → Buy | Citigroup |
| 12/10/2024 | $43.00 | Hold | Jefferies |
| 9/19/2024 | $42.00 → $50.00 | Neutral | UBS |
| 9/5/2024 | $40.00 → $57.00 | Hold → Buy | Craig Hallum |
| 3/4/2024 | $70.00 → $42.00 | Neutral → Sell | UBS |
| 2/14/2024 | $66.00 → $37.00 | Neutral → Underweight | JP Morgan |
4 - QuidelOrtho Corp (0001906324) (Issuer)
4 - QuidelOrtho Corp (0001906324) (Issuer)
4 - QuidelOrtho Corp (0001906324) (Issuer)
SAN DIEGO, Jan. 22, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL), a global leader in in vitro diagnostics, has released episode 55 of its Science Bytes podcast, featuring Michelle Mullens, Global Portfolio Marketing Manager for Transfusion Medicine. With decades of experience in blood banking and immunohematology, Mullens shares insights into the pressures on today's blood supply and the importance of consistent donor engagement. Key insights: Everyday and climate-driven emergencies strain supply: Routine trauma, traffic injuries and increasingly frequent weather
SAN DIEGO, Jan. 21, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, announced today that it will report its financial results for the fourth quarter and full year 2025 ended December 28, 2025, after the market close on Wednesday, February 11, 2026. Following the release of financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results. Interested parties can access the call from the "Events & Presentations" section of the "
SAN DIEGO, Dec. 18, 2025 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL), a global leader in in vitro diagnostics, has released Episode 54 of its Science Bytes podcast, featuring Jonathan Siegrist, PhD, Executive Vice President of Research & Development and Chief Technology Officer at QuidelOrtho. Dr. Siegrist is a recognized leader in molecular diagnostics and biomedical engineering, driving innovation and next-generation diagnostic solutions. Key insights include: Faster cardiac care: High-sensitivity troponin testing accelerates diagnosis and treatment for cardiac pat
Citigroup downgraded QuidelOrtho from Buy to Neutral and set a new price target of $33.00
Jefferies upgraded QuidelOrtho from Hold to Buy and set a new price target of $44.00
Citigroup upgraded QuidelOrtho from Neutral to Buy and set a new price target of $50.00 from $44.00 previously
4 - QuidelOrtho Corp (0001906324) (Issuer)
4 - QuidelOrtho Corp (0001906324) (Issuer)
4 - QuidelOrtho Corp (0001906324) (Issuer)
144 - QuidelOrtho Corp (0001906324) (Subject)
8-K - QuidelOrtho Corp (0001906324) (Filer)
8-K - QuidelOrtho Corp (0001906324) (Filer)
SAN DIEGO, Jan. 21, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, announced today that it will report its financial results for the fourth quarter and full year 2025 ended December 28, 2025, after the market close on Wednesday, February 11, 2026. Following the release of financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results. Interested parties can access the call from the "Events & Presentations" section of the "
― Total revenue of $700 million; excluding COVID-19 and Donor Screening, revenue grew mid-single digits, demonstrating solid underlying growth and momentum ― ― Successful completion of debt refinancing, enhancing financial flexibility through improved terms and reduced amortization obligations ― ― Full-year 2025 revenue and adjusted EBITDA guidance ranges narrowed; adjusted diluted EPS updated to reflect debt refinancing ― Third Quarter 2025 Results(all comparisons are to the prior year period) Total revenue was $700 million, as reportedNon-respiratory revenue was $588 million, an increase of 5% as reported and 4% in constant currency; excluding Donor S
SAN DIEGO, Oct. 22, 2025 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, announced today that it will report its financial results for the third quarter 2025 ended September 28, 2025, after the market closes on Wednesday, November 5, 2025. Following the release of financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results. Interested parties can access the call from the "Events & Presentations" section of the "Investor Relat
SC 13G/A - QuidelOrtho Corp (0001906324) (Subject)
SC 13D/A - QuidelOrtho Corp (0001906324) (Subject)
SC 13G/A - QuidelOrtho Corp (0001906324) (Subject)
SAN DIEGO, Aug. 19, 2025 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, welcomes Erich Wolff as Executive Vice President, Strategy & Corporate Development. In this role, Mr. Wolff will report directly to President and Chief Executive Officer Brian Blaser, and he will lead the Company's enterprise strategy, business development, government affairs and portfolio management functions. Mr. Wolff brings over two decades of leadership experience in strategy, M&A and business development across the heal
Veteran Healthcare CEOs John R. Chiminski and R. Scott Huennekens Bring Deep Industry Experience, Operational Expertise and Financial Acumen to the QuidelOrtho Board QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the appointments of John R. Chiminski and R. Scott Huennekens to its board of directors (the "Board"), effective December 6, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210769572/en/R. Scott Huennekens (Photo: Business Wire) T
Jonathan Siegrist appointed as EVP of R&D and CTO QuidelOrtho Corporation (NASDAQ:QDEL), a global leader in innovative diagnostic solutions, is pleased to announce the appointment of Jonathan Siegrist, PhD, as its new Executive Vice President of Research and Development (R&D) and Chief Technology Officer (CTO), effective as of October 7, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241009251239/en/Jonathan Siegrist, EVP of R&D and CTO, QuidelOrtho (Photo: Business Wire) Siegrist brings a wealth of industry expertise and leadership experience with over 15 years in molecular diagnostics, microfluidic platforms, and biomedi